Of the patients with ALL and BCR-ABL fusions, the 5-year OS was 45.6%, consistent with the outcomes seen before the use of ABL-class tyrosine kinase inhibitors (44). This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.